N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide: A novel reversible antimitotic agent inhibiting cancer cell motility.

[1]  Roberto Therón,et al.  JADOPPT: java based AutoDock preparing and processing tool , 2016, Bioinform..

[2]  Samir Mehndiratta,et al.  Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents. , 2014, Bioorganic & medicinal chemistry.

[3]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII. , 2014, European journal of medicinal chemistry.

[4]  A. Bravin,et al.  The combined therapeutical effect of metal-based drugs and radiation therapy: the present status of research. , 2014, Current medicinal chemistry.

[5]  Manuel Serrano,et al.  Cellular senescence: from physiology to pathology , 2014, Nature Reviews Molecular Cell Biology.

[6]  A. Rescifina,et al.  Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling. , 2014, European journal of medicinal chemistry.

[7]  J. Luz,et al.  Glucocorticoid receptor modulators informed by crystallography lead to a new rationale for receptor selectivity, function, and implications for structure-based design. , 2014, Journal of medicinal chemistry.

[8]  Huiling Yang,et al.  Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease. , 2014, Bioorganic & medicinal chemistry letters.

[9]  Eiman Mukhtar,et al.  Targeting Microtubules by Natural Agents for Cancer Therapy , 2014, Molecular Cancer Therapeutics.

[10]  K. Haridas,et al.  Synthesis and characterization of new N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)amide/sulfonamide derivatives as possible antimicrobial and antitubercular agents. , 2014, European journal of medicinal chemistry.

[11]  G. Schneider,et al.  Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1. , 2013, Bioorganic & medicinal chemistry.

[12]  Marie Lopez,et al.  Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment. , 2013, Bioorganic & medicinal chemistry letters.

[13]  C. Galiana-Roselló,et al.  In vitro and in vivo antileishmanial and trypanocidal studies of new N-benzene- and N-naphthalenesulfonamide derivatives. , 2013, Journal of medicinal chemistry.

[14]  K. C. Sivakumar,et al.  Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics , 2013, Molecular Cancer Therapeutics.

[15]  Robert Schmieder,et al.  Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. , 2013, Neoplasia.

[16]  F. Giles,et al.  The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance , 2013, British Journal of Cancer.

[17]  J. Naval,et al.  Antimitotic drugs in cancer chemotherapy: promises and pitfalls. , 2013, Biochemical pharmacology.

[18]  V. Nair,et al.  Synthesis and anti-inflammatory activity of celecoxib like compounds , 2013, Journal of enzyme inhibition and medicinal chemistry.

[19]  Sandeep Lohan,et al.  Design and synthesis of novel 4-(4-oxo-2-arylthiazolidin-3-yl)benzenesulfonamides as selective inhibitors of carbonic anhydrase IX over I and II with potential anticancer activity. , 2013, European journal of medicinal chemistry.

[20]  Z. Gu,et al.  Discovery of N-(4'-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication. , 2013, Bioorganic & medicinal chemistry letters.

[21]  E. Reddy,et al.  Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. , 2013, Journal of medicinal chemistry.

[22]  S. Agarwal,et al.  Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents. , 2013, Bioorganic & medicinal chemistry.

[23]  H. Moon,et al.  Synthesis of Novel N-(2-Hydroxyphenyl)arylsulfonamides as Selective HDAC Inhibitory and Cytotoxic Agents , 2013 .

[24]  C. Supuran,et al.  Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013) , 2013, Expert opinion on therapeutic patents.

[25]  S. Shah,et al.  Synthetic Routes of Sulfonamide Derivatives: A Brief Review , 2013 .

[26]  D. Lauffenburger,et al.  Targeting tumor cell motility as a strategy against invasion and metastasis. , 2013, Trends in pharmacological sciences.

[27]  Z. Binkhathlan,et al.  P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. , 2013, Current cancer drug targets.

[28]  S. Ralston,et al.  Development of triarylsulfonamides as novel anti-inflammatory agents. , 2013, Bioorganic & medicinal chemistry letters.

[29]  S. Singh,et al.  Sulphonamides: Deserving class as MMP inhibitors? , 2013, European journal of medicinal chemistry.

[30]  U. Krishnan,et al.  Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy. , 2013, Anti-cancer agents in medicinal chemistry.

[31]  C. Supuran,et al.  Secondary and tertiary sulfonamides: a patent review (2008 – 2012) , 2013, Expert opinion on therapeutic patents.

[32]  S. Shah,et al.  Recent advances in medicinal chemistry of sulfonamides. Rational design as anti-tumoral, anti-bacterial and anti-inflammatory agents. , 2012, Mini reviews in medicinal chemistry.

[33]  A. Husain,et al.  Heterocyclic compounds as carbonic anhydrase inhibitor , 2012, Journal of enzyme inhibition and medicinal chemistry.

[34]  C. Rosano,et al.  Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents. , 2012, European journal of medicinal chemistry.

[35]  Zhe-Sheng Chen,et al.  Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance , 2012, Marine drugs.

[36]  Bibo Li,et al.  Identification of selective tubulin inhibitors as potential anti-trypanosomal agents. , 2012, Bioorganic & medicinal chemistry letters.

[37]  Yehuda G Assaraf,et al.  Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[38]  S. Singh,et al.  Cyclin Dependent Kinase as Significant Target for Cancer Treatment , 2012 .

[39]  Duane D. Miller,et al.  An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.

[40]  C. Zhu,et al.  Sulfonyl group-containing compounds in the design of potential drugs for the treatment of diabetes and its complications. , 2012, Current medicinal chemistry.

[41]  R. C.-Gaudreault,et al.  Synthesis, Biological Evaluation, and Structure–Activity Relationships of Novel Substituted N-Phenyl Ureidobenzenesulfonate Derivatives Blocking Cell Cycle Progression in S-Phase and Inducing DNA Double-Strand Breaks , 2012, Journal of medicinal chemistry.

[42]  P. Dráber,et al.  Tubulins as therapeutic targets in cancer: from bench to bedside. , 2012, Current pharmaceutical design.

[43]  A. Kamal.  Synthesis and Apoptosis Inducing Ability of New Anilino‐Substituted Pyrimidine Sulfonamides as Potential Anticancer Agents. , 2012 .

[44]  D. Zheleva,et al.  Aurora kinase inhibitors: Progress towards the clinic , 2012, Investigational New Drugs.

[45]  T. Mitchison,et al.  Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction , 2012, Molecular biology of the cell.

[46]  N. Dhanesha,et al.  Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[47]  A. Kamal,et al.  Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents. , 2011, European journal of medicinal chemistry.

[48]  E. Noaman,et al.  Evaluation of the Antitumor and Radiosynthetizing Activity of a Novel Quinoline Sulfonamide Derivative (PIQSA) as a Histone Deacetylase Inhibitor , 2011 .

[49]  Yin Luo,et al.  Metronidazole acid acyl sulfonamide: a novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[50]  J. Bartek,et al.  More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance , 2011, Nature Cell Biology.

[51]  Hai‐Liang Zhu,et al.  Synthesis, biological evaluation, and molecular modeling of cinnamic acyl sulfonamide derivatives as novel antitubulin agents. , 2011, Bioorganic & medicinal chemistry.

[52]  M. Al-Dosari,et al.  Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety. , 2011, European journal of medicinal chemistry.

[53]  Melvin J. Yu,et al.  Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. , 2011, Cancer research.

[54]  J. Chen,et al.  Design, synthesis, and biological evaluation of novel N-γ-carboline arylsulfonamides as anticancer agents. , 2010, Bioorganic & medicinal chemistry.

[55]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[56]  Hsueh-Wei Chang,et al.  Additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells. , 2010, Life sciences.

[57]  A. Kozubík,et al.  FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. , 2010, Bone.

[58]  A. Gudkov,et al.  Pseudo-DNA damage response in senescent cells , 2009, Cell cycle.

[59]  J. O’Sullivan,et al.  Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro , 2009, British Journal of Cancer.

[60]  M. E. González-Rosende,et al.  In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide. , 2009, Bioorganic & medicinal chemistry.

[61]  Raimond B G Ravelli,et al.  Variations in the colchicine-binding domain provide insight into the structural switch of tubulin , 2009, Proceedings of the National Academy of Sciences.

[62]  M. Nishiyama,et al.  Recent advances in cancer chemotherapy: current strategies, pharmacokinetics, and pharmacogenomics. , 2009, Advanced drug delivery reviews.

[63]  R. Shao,et al.  N-(2,6-Dimethoxypyridine-3-yl)-9-Methylcarbazole-3-Sulfonamide as a Novel Tubulin Ligand against Human Cancer , 2008, Clinical Cancer Research.

[64]  Jian-Dong Jiang,et al.  Novel diaryl or heterocyclic sulfonamides as antimitotic agents. , 2008, Anti-cancer agents in medicinal chemistry.

[65]  V. Yang,et al.  Human cancer cells commonly acquire DNA damage during mitotic arrest. , 2007, Cancer research.

[66]  Kiran V. Mahasenan,et al.  Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents. , 2007, Bioorganic & medicinal chemistry.

[67]  Mathias Schmidt,et al.  Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[68]  J. Bartek,et al.  DNA damage checkpoints: from initiation to recovery or adaptation. , 2007, Current opinion in cell biology.

[69]  J. Nylandsted,et al.  Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. , 2007, Cancer research.

[70]  P. Brown,et al.  Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. , 2007, Biochemical pharmacology.

[71]  D. Zaharevitz,et al.  A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. , 2005, Journal of medicinal chemistry.

[72]  A. Ganesan,et al.  Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity , 2005, Apoptosis.

[73]  S. Horwitz,et al.  The Microtubule Stabilizing Agent Discodermolide is a Potent Inducer of Accelerated Cell Senescence , 2005, Cell cycle.

[74]  K. Gumireddy,et al.  Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. , 2004, Bioorganic & medicinal chemistry letters.

[75]  J. Bartek,et al.  Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. , 2004, DNA repair.

[76]  M. Weller,et al.  P‐Glycoprotein and Multidrug Resistance‐associated Protein Mediate Specific Patterns of Multidrug Resistance in Malignant Glioma Cell Lines, but not in Primary Glioma Cells , 2003, Brain pathology.

[77]  K. Wood,et al.  Past and future of the mitotic spindle as an oncology target. , 2001, Current opinion in pharmacology.

[78]  M. Venable,et al.  Ceramide induces expression of the senescence histochemical marker, β-galactosidase, in human fibroblasts , 2000, Mechanisms of Ageing and Development.

[79]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[80]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[81]  K. Lee,et al.  Antitumor agents. 141. Synthesis and biological evaluation of novel thiocolchicine analogs: N-acyl-, N-aroyl-, and N-(substituted benzyl)deacetylthiocolchicines as potent cytotoxic and antimitotic compounds. , 1993, Journal of medicinal chemistry.

[82]  M. Oshimura,et al.  Recurrent micronucleation through cell cycle progression in the presence of microtubule inhibitors. , 2015, Cell structure and function.

[83]  Joachim Müller,et al.  New approaches for the identification of drug targets in protozoan parasites. , 2013, International review of cell and molecular biology.

[84]  Kalyani,et al.  Targeted Drug Delivery to the Nucleus and its Potential Role in Cancer Chemotherapy , 2013 .

[85]  G. Capellá,et al.  Recent advances in cancer therapy: an overview. , 2010, Current pharmaceutical design.

[86]  T. Haritunians,et al.  Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. , 2008, Oncology reports.

[87]  Goberdhan P Dimri,et al.  Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. , 2007, Methods in molecular biology.